EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Genexine Inc (095700) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Genexine Inc KRW 3,255, price KRW 2,770, upside +17.5%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR · ISIN KR7095700001

GI Thin data Oct 2, 2026

Genexine Inc

095700 · KQ

SpeculativeUpside exists, but weak quality makes the signal speculative.

Fair value 3,255 KRW · Undervalued (+17.5%)
Low debt
Ranks above peers (6/7)
Quality 37/100
Weak Growth (revenue 5y −24.4 %/yr in KRW)
Negative free cash flow
Narrow moat 12/100
Thin data
Watch Genexine Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

78,382 KRW 2,195 KRW Fair Value 3,255 KRW May 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.

How to read this chart

60‑month range 2,195 KRW – 78,382 KRW · fair‑value band 2,429 KRW – 4,858 KRW · the 2,770 KRW price screens below the 3,255 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 2, 2026.

Follow Genexine in your weekly email

Every Wednesday you see whether Genexine is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Genexine, Inc., together with its subsidiaries, operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally.

Show more

Genexine, Inc., together with its subsidiaries, operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally. The company develops its products through its hybrid Fc platform, a proprietary technology designed to develop long-acting protein drugs; and the DNA vaccine platform that is used to elicit immune responses in the human body to fight viral infection and cancer cells. Its product pipeline includes GX-H9, which is in Phase II and III clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E4 that is in Phase III clinical trials for the treatment of anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; GX-I7, a product candidate in Phase I and II clinical trials to treat solid tumors, lymphopenia, and COVID-19; GX-P1, which is in Phase I clinical trials for the treatment of autoimmune diseases and transplantation; and GX-G6 that is in Phase II clinical trials for the treatment of diabetes. The company is also developing GX-188E that is in Phase II clinical trials for the treatment of cervical cancer, and head and neck cancer. The company was formerly known as Genexine Co., Ltd. and changed its name to Genexine, Inc. in March 2013. Genexine, Inc. was founded in 1999 and is headquartered in Seoul, South Korea.

Stock analysis

Genexine Inc (095700) currently trades at 2,770 KRW, while our model-based Fair Value estimate is 3,255 KRW, implying the stock looks roughly 14.9% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 2,429 KRW (bear) to 4,858 KRW (bull), the price of 2,770 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Genexine Inc reported revenue of 4.6B KRW in FY2025 versus 36.8B KRW in FY2021, a compound −40.6%/yr. Reported net income was −27.2B KRW in FY2025.

Key figures

Market cap 126B KRW (≈ $93.8M) · P/S ratio 21.9 · Return on equity −17.3% · Return on assets (EBIT) −8.7% · Operating margin −610% · Revenue (TTM) 5.8B KRW · Revenue growth (YoY) +200% · Free cash flow −44.3B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).

What moves the price

The share trades about 61% below its 52-week high and 26% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 18%, 095700 screens cheaper than that median.

Fair Value models

Bear 2,429 KRW Fair Value 3,255 KRW Bull 4,858 KRW
Price 2,770 KRW · Upside +17.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 2,713 KRW 3,635 KRW 5,426 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 2,713 KRW 3,635 KRW 5,426 KRW 54

Open the full fair value analysis →

Notify me when 095700 reaches fair value

Put 095700 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 37/100

Of which business quality 37 · Market factors (momentum, volatility) 28

Profitability 0
Margins and returns on capital today
Quality Growth 90
Are margins and returns improving?
Cashflow 13
Earnings quality: real cash, not paper profit
Fin. Strength 47
Balance sheet, leverage, solvency risk
Investment 67
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 25
Price trend over the last 3–12 months (market factor)
52W Momentum 6
Distance to the 52-week high (market factor)
Net Issuance 40
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+56.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−34.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−24.4%
Start year 2020 (pandemic). Over 10 years: −17.8% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−251.3% (2020) → −788.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 095700, get fair value alerts →

Compare Genexine Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 605 stocks

Beats the industry median on 5/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 37 · Below median
Fair Value upside +17.5% · Top 25%
Profitability
Return on assets −6.7% · Above median
Growth and dividend
Revenue growth 199.6% · Top 25%
Balance sheet
Debt / equity 0.03× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/S (TTM) 0.02× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)57 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)99 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Genexine Inc · Fair Value
3,255 KRW +15%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Genexine Inc Fair Value". https://www.fairvalue-calculator.com/stock/095700

Frequently asked questions

Is Genexine Inc (095700) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of 3,255 KRW versus a price of 2,770 KRW, about +18% upside (undervalued).
What is the fair value of 095700?
Our model-based fair value for Genexine Inc is 3,255 KRW (as of Oct 2, 2026), built from audited fundamentals. The current price: 2,770 KRW.
What is the quality score of 095700?
Genexine Inc has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Genexine Inc (095700)?
Our model-based price target is the fair value of 3,255 KRW (as of Oct 2, 2026) from 1 valuation models. Cautious scenario 2,429 KRW, optimistic scenario 4,858 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Genexine Inc stock forecast for 2026?
Our models put fair value at 3,255 KRW, about +18% upside versus a price of 2,770 KRW (undervalued). Cautious scenario 2,429 KRW, optimistic scenario 4,858 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Genexine Inc (095700)?
Genexine Inc reported trailing-twelve-month revenue of about 5.8B KRW (latest available figure, as of Oct 2, 2026).
What is the intrinsic value of Genexine Inc (095700)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Genexine Inc it is 3,255 KRW per share (as of Oct 2, 2026), against a price of 2,770 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Genexine Inc stock overvalued or undervalued in 2026?
As of Oct 2, 2026, 095700 trades below its calculated fair value: price 2,770 KRW, fair value 3,255 KRW, a gap of about +18% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 095700?
No. The price is what the market pays today (2,770 KRW); the fair value is what the company's own numbers justify (3,255 KRW). For Genexine Inc the two are 484.88 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Genexine Inc worth?
The market values Genexine Inc at about 126B KRW (market capitalisation, as of Oct 2, 2026). Per share that is 2,770 KRW; our models calculate a fair value of 3,255 KRW per share.
What do the bullish and bearish scenarios say about 095700?
Our models span a range for Genexine Inc: cautious scenario 2,429 KRW, base 3,255 KRW, optimistic 4,858 KRW per share (as of Oct 2, 2026, price 2,770 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Genexine Inc (095700)?
Balance-sheet figures for Genexine Inc (as of Oct 2, 2026): return on equity −17.3%, debt of 0.03 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is 095700 from its 52-week high?
Genexine Inc trades at 2,770 KRW, about 61% below its 52-week high of 7,100 KRW and 26% above the low of 2,195 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 3,255 KRW is for.
Which stocks are comparable to Genexine Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Genexine Inc stock attractive at the current price?
The data as of Oct 2, 2026: price 2,770 KRW, calculated fair value 3,255 KRW (+18%), Quality Score 37/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 095700 calculated?
We run Genexine Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 3,255 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Genexine Inc currently trades 15 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Genexine Inc (095700)?
The closing price on Oct 2, 2026 was 2,770 KRW. Our model-based fair value is 3,255 KRW, about +18% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Genexine Inc right now?
A fairly wide model range (2,429 KRW to 4,858 KRW) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Genexine Inc

How large is the market capitalisation of Genexine Inc (095700)?
The market capitalisation of Genexine Inc is 126B KRW (≈ $93.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Genexine Inc (095700)?
The price-to-sales ratio of Genexine Inc is 21.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the return on equity of Genexine Inc (095700)?
The return on equity (ROE) of Genexine Inc is −17.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Genexine Inc (095700)?
On an EBIT basis the return on assets of Genexine Inc is −8.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Genexine Inc (095700)?
The operating margin of Genexine Inc is −610% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Genexine Inc (095700)?
Revenue at Genexine Inc is growing +200% versus a year earlier (3y avg −34.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Genexine Inc (095700) generate?
The free cash flow of Genexine Inc is −44.3B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Genexine Inc (095700) carry?
The net debt of Genexine Inc is 98.6B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Genexine Inc in the live analysis

One click puts Genexine Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.